The No Surprises Act was designed to protect patients from unexpected out-of-network bills. Its dispute resolution mechanism, almost accidentally, created one of the more interesting arbitrage dynamics in healthcare finance.
When a patient receives care from an out-of-network provider at an in-network facility—the classic surprise billing scenario in emergency medicine and anesthesia—the No Surprises Act’s Independent Dispute Resolution process governs how the provider and payer resolve payment disagreements. The arbitration anchor is the Qualifying Payment Amount: the median contracted rate that the payer has negotiated with in-network providers for the same or similar service in the same geographic area. Arbitrators are instructed to select between the payer’s offer and the provider’s offer, choosing whichever is closer to the QPA unless credible evidence supports a material deviation.
The QPA is, in other words, a function of the negotiated rate distribution that MedPricer.org tracks. A provider whose out-of-network rates significantly exceed the median commercial rate in their market faces an unfavorable arbitration environment—not because their rates are illegitimate, but because the statutory anchor is set at median market rates rather than at their specific contract history. Conversely, a payer whose QPA calculation draws on a rate distribution that has been suppressed by below-market contracts in its network faces arbitration offers that may exceed its QPA systematically.
For PE-backed physician groups in emergency medicine and anesthesia—the specialties most affected by surprise billing—this creates a specific analytical task: understanding where their actual rates fall relative to the QPA in each market where they operate, and modeling what an IDR-determined payment would mean for their revenue per encounter. Groups that built their revenue models on rates materially above market median face structural revenue compression that their pre-NSA pro formas did not anticipate.
CMS data on IDR outcomes—which the agency is required to publish under the NSA—provides an early indicator of how arbitrators are resolving cases and at what payment levels. The combination of MedPricer’s market rate distribution data and CMS’s IDR outcome data creates a reasonably complete picture of the arbitration landscape for specific specialties and geographies. Early IDR data from CMS showed providers winning the majority of arbitration disputes, which suggested that initial QPA calculations were below prevailing rates in many markets—a finding that subsequently influenced regulatory adjustments to the QPA methodology.
For investors in PE-backed physician groups, this regulatory uncertainty is the central risk. If the QPA methodology is set conservatively—anchoring to a suppressed median—the groups’ out-of-network revenue is compressed. If it is set generously, their leverage in negotiations with payers who previously paid low rates is enhanced, because the arbitration backstop guarantees a floor that the payer cannot credibly offer below.
The investment implication runs through acquisition pricing. PE firms acquiring physician groups have historically valued out-of-network revenue streams at multiples that reflected pre-NSA rate expectations. Those expectations are now subject to regulatory revision. A fund evaluating a PE-backed physician group acquisition should model NSA-adjusted revenue using MedPricer’s market rate data to estimate the QPA range, then stress-test the acquisition multiple against the range of plausible IDR outcomes.
This is less a trading strategy than a valuation discipline—a way of ensuring that the out-of-network revenue embedded in a physician group’s EBITDA is priced at regulatory reality rather than at historical rates that the NSA has fundamentally restructured. The groups that emerge with their valuations intact will be those whose in-network rates, negotiated with full knowledge of the QPA floor, reflect a realistic assessment of what arbitration would produce.
